<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2377">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369794</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19 BATTLE trial</org_study_id>
    <nct_id>NCT04369794</nct_id>
  </id_info>
  <brief_title>COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement</brief_title>
  <acronym>BATTLE</acronym>
  <official_title>COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Infectologia Emílio Ribas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontifícia Universidade Católica de Campinas, PUC-Campinas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculty of Medicine of Ribeirão Preto (FMRP-USP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Hospital Dr. Leandro Franceschini, Sumaré, Unicamp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paulinia Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To date, there is no vaccine or treatment with proven efficiency against COVID-19, and the
      transmissibility of the SARS-CoV-2 virus can be inferred by its identification in the
      oro-nasopharynx. The bacillus Calmette Guérin (BCG) has the potential for cross-protection
      against viral infections. This study evaluates the impact of previous (priming effect, from
      the titer of anti-BCG interferon-gamma) or current BCG exposure (boost with intradermal
      vaccine) on 1) clinical evolution of COVID-19; 2) elimination of SARS-CoV-2 at different
      times and disease phenotypes; and 3) seroconversion rate and titration (anti-SARS-CoV-2 IgA,
      IgM, and IgG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, double-blind, multicentre study with international design
      collaboration with central clinical and mechanistic outcomes with public health implications
      both epidemiological and therapeutic in the context of the pandemic of COVID-19, an emerging
      disease, which quickly disrupted health services including Brazil's Unified Health System
      (SUS), as well as the entire productive force and economy worldwide. Because it is recent,
      the basic evidence related to infection, such as incubation period, time of transmissibility,
      and seroconversion, is little known and the proposal's goals have the potential to redirect
      the vaccine. Exploring bacillus Calmette Guerin (BCG) that presents significant potential for
      immune activation, with recognized safety in decades of previous experience and clear
      potential in the context under analysis, with low cost and available, ensuring wide
      accessibility, especially in the context of SUS, on which it depends especially the most
      vulnerable portion of the Brazilian population, notably in the COVID-19 pandemic.
      Non-specific effects of BCG caused by monocyte epigenetic reprogramming may result in
      increased production of pro-inflammatory cytokines, conferring innate (trained) immunity and
      protection against viral infections, including SARS-CoV-2 with the potential to positively
      impact clinical evolution, viral elimination, and seroconversion of COVID-19 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evolution of COVID-19</measure>
    <time_frame>45 days of symptoms onset or diagnosis</time_frame>
    <description>Classified as mild, moderate and severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 elimination</measure>
    <time_frame>7 days of symptoms onset or diagnosis</time_frame>
    <description>Virus detection by PCR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion rate and titration</measure>
    <time_frame>7 days of symptoms onset or diagnosis</time_frame>
    <description>Titration of anti SARS-CoV-2 IgA, IgM and IgG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic adverse events to BCG vaccination</measure>
    <time_frame>3 months</time_frame>
    <description>Classified according to type and severity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>SARS-CoV-2 elimination</measure>
    <time_frame>21 days of symptoms onset or diagnosis</time_frame>
    <description>Virus detection by PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>21 days of symptoms onset or diagnosis</time_frame>
    <description>Titration of anti SARS-CoV-2 IgA, IgM and IgG</description>
  </other_outcome>
  <other_outcome>
    <measure>SARS-CoV-2 elimination</measure>
    <time_frame>45 days of symptoms onset or diagnosis</time_frame>
    <description>Virus detection by PCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion rate and titration</measure>
    <time_frame>45 days of symptoms onset or diagnosis</time_frame>
    <description>Titration of anti SARS-CoV-2 IgA, IgM and IgG</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19</condition>
  <condition>Therapeutic Vaccine</condition>
  <condition>BCG</condition>
  <condition>SARS-CoV 2</condition>
  <condition>Transmission</condition>
  <arm_group>
    <arm_group_label>BCG vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCG Group (n = 500): 0.1 ml of lyophilized, live and attenuated BCG intradermal vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group (n = 500): 0.9% saline solution in the same volume as BCG vaccine in a single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose</description>
    <arm_group_label>BCG vaccine</arm_group_label>
    <other_name>Calmette Guerin bacillus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% saline in the same volume as the BCG vaccine in a single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age;

          -  laboratory or clinical-epidemiological confirmation of COVID-19 (history of close or
             home contact with a laboratory-confirmed case who has fever or at least one of the
             respiratory signs or symptoms, in the last 14 days after contact, and for which it was
             not possible to carry out the specific laboratory investigation)

        Exclusion Criteria:

          -  Immunosuppressed patients of any kind;

          -  Pregnant women;

          -  More than 14 days from the onset of symptoms;

          -  Not accept participation or non-signature of the IC;

          -  Undiagnosed cases, suspected or probable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo O Reis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UroScience, University of Campinas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen L Ferrari, PhD</last_name>
    <phone>+55 19 3521 7481</phone>
    <email>karenferrari@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-887</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen L Ferrari, PhD</last_name>
      <phone>+551935217116</phone>
      <email>karenferrari@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonardo O Reis, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Leonardo Oliveira Reis</investigator_full_name>
    <investigator_title>Professor Livre Docente</investigator_title>
  </responsible_party>
  <keyword>BCG</keyword>
  <keyword>Therapeutic Vaccine</keyword>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV 2</keyword>
  <keyword>Interferon Gamma</keyword>
  <keyword>Immunoglobulin</keyword>
  <keyword>Immunemodulation</keyword>
  <keyword>Transmission</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

